The Pharma Data

NOVEMBER 9, 2021

Molnupiravir was constructed at Medicine Inventions at Emory ( DRIVE), LLC, a not-for- profit biotechnology company wholly possessed by Emory University; Emory/ DRIVE entered some exploration backing from theU.S.

Medicine 52

Medicine Radiology Development Drugs 52

The Pharma Data

JUNE 28, 2021

The companies acquired by Bayer, Noria and PSMA Therapeutics, have exclusive world-wide rights to technology licensed from Weill Cornell Medicine (New York, NY, USA) and Johns Hopkins University (Baltimore, MD, USA). Noria was founded by Dr. John Babich, Chief, Radiopharmaceutical Sciences in Radiology at Weill Cornell Medicine.

Licensing 52

Licensing Licensing Medicine Development 52

pharmaphorum

APRIL 7, 2021

In its second licensing deal in the radio-oncology area in consecutive weeks, Novartis has agreed a $1.3 billion-plus alliance with UK biotech Artios Pharma to develop precision medicines for cancer. billion licensing deal, and is due to filed for regulatory approval in the US and EU this year.

DNA 52

DNA Licensing Licensing Gene Therapy 52

The Pharma Data

MARCH 25, 2022

This includes about three million people in the EU who are immunocompromised or being treated with immunosuppressive medicines.(1). 5-7) New data from Washington University School of Medicine demonstrated Evusheld retained potent neutralising activity against the emerging and highly transmissible BA.2

Antibody 52

Antibody In-Vivo Medicine Vaccination 52

The Pharma Data

MARCH 29, 2022

4-6 New data from Washington University School of Medicine demonstrated Evusheld retained potent neutralising activity against the emerging and highly transmissible BA.2 4-6 New data from Washington University School of Medicine demonstrated Evusheld retained potent neutralising activity against the emerging and highly transmissible BA.2

Antibody 52

Antibody In-Vivo Vaccination Vaccine 52

The Pharma Data

DECEMBER 23, 2020

Department of Defense (DoD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in coordination with the Office of the Assistant Secretary of Defense for Health Affairs (OASD(HA)) and the Defense Health Agency (DHA). About INOVIO’s DNA Medicines Platform.

DNA 40

DNA Vaccination Vaccine Immune Response 40

pharmaphorum

SEPTEMBER 30, 2022

According to Prof Peter Passmore, an ageing and geriatric medicine specialist at Queen’s University Belfast, the benefits “seem to be small and the debate will be around how clinically relevant the changes are in CDR SB.” point advantage.

Clinical Trials 52

Clinical Trials Clinical Trials Sales Drugs 52